Accelerating protein biomarker discovery and translation from proteomics research for clinical utility

被引:10
作者
Chen, Jiwen [1 ]
Zheng, Naiyu [2 ]
机构
[1] Bristol Myers Squibb, Small Mol Drug Discovery, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb, Translat Med, Princeton, NJ 08543 USA
关键词
biomarker qualification; clinical biomarker utility; mass spectrometry; protein biomarker discovery; proteomics research; targeted proteomics; TARGETED PROTEOMICS; CANCER; QUANTIFICATION; SENSITIVITY; VALIDATION; INTERFACE; QUALITY; DESIGN; ASSAYS; PHASE;
D O I
10.4155/bio-2020-0198
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Discovery proteomics research has made significant progress in the past several years; however, the number of protein biomarkers deployed in clinical practice remains rather limited. There are several scientific and procedural gaps between discovery proteomics research and clinical implementation, which have contributed to poor biomarker validity and few clinical applications. The complexity and low throughput of proteomics approaches have added additional barriers for biomarker assay translation to clinical applications. Recently, targeted proteomics have become a powerful tool to bridge the biomarker discovery to clinical validation. In this perspective, we discuss the challenges and strategies in proteomics research from a clinical perspective, and propose several recommendations for discovery proteomics research to accelerate protein biomarker discovery and translation for future clinical applications.
引用
收藏
页码:1469 / 1481
页数:13
相关论文
共 80 条
[1]   High-Throughput, Sensitive LC-MS Quantification of Biotherapeutics and Biomarkers Using Antibody-Free, Peptide-Level, Multiple-Mechanism Enrichment via Strategic Regulation of pH and Ionic and Solvent Strengths [J].
An, Bo ;
Zhang, Ming ;
Pu, Jie ;
Shen, Shichen ;
Qu, Yang ;
Chen, Yuan-Ju ;
Huo, Shihan ;
Wang, Xue ;
Polli, Joseph Ryan ;
Balthasar, Joseph P. ;
Herzog, Denis ;
Ferrari, Luca ;
Staack, Roland F. ;
Richter, Wolfgang F. ;
Otteneder, Michael B. ;
Benincosa, Lisa J. ;
Zhou, Shaolian ;
Vazvaei, Faye ;
Qu, Jun .
ANALYTICAL CHEMISTRY, 2019, 91 (05) :3475-3483
[2]   An industry perspective on the US FDA biomarker qualification effort [J].
Arnold, Mark E. .
BIOANALYSIS, 2018, 10 (12) :913-916
[3]   A Novel LC System Embeds Analytes in Pre-formed Gradients for Rapid, Ultra-robust Proteomics [J].
Bache, Nicolai ;
Geyer, Philipp E. ;
Bekker-Jensen, Dorte B. ;
Hoerning, Ole ;
Falkenby, Lasse ;
Treit, Peter V. ;
Doll, Sophia ;
Paron, Igor ;
Mueller, Johannes B. ;
Meier, Florian ;
Olsen, Jesper V. ;
Vorm, Ole ;
Mann, Matthias .
MOLECULAR & CELLULAR PROTEOMICS, 2018, 17 (11) :2284-2296
[4]   Development of High-Throughput Chemical Extraction Techniques and Quantitative HPLC-MS/MS (SRM) Assays for Clinically Relevant Plasma Proteins [J].
Barton, Chris ;
Kay, Richard G. ;
Gentzer, Wolfgang ;
Vitzthum, Frank ;
Pleasance, Steve .
JOURNAL OF PROTEOME RESEARCH, 2010, 9 (01) :333-340
[5]   A Compact Quadrupole-Orbitrap Mass Spectrometer with FAIMS Interface Improves Proteome Coverage in Short LC Gradients [J].
Bekker-Jensen, Dorte B. ;
Martinez-Val, Ana ;
Steigerwald, Sophia ;
Ruther, Patrick ;
Fort, Kyle L. ;
Arrey, Tabiwang N. ;
Harder, Alexander ;
Makarov, Alexander ;
Olsen, Jesper, V .
MOLECULAR & CELLULAR PROTEOMICS, 2020, 19 (04) :716-729
[6]   What is targeted proteomics? A concise revision of targeted acquisition and targeted data analysis in mass spectrometry [J].
Borras, Eva ;
Sabido, Eduard .
PROTEOMICS, 2017, 17 (17-18)
[7]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[8]   MISSING THE MARK [J].
Buchen, Lizzie .
NATURE, 2011, 471 (7339) :428-432
[9]   Monitoring protein communities and their responses to therapeutics [J].
Budayeva, Hanna G. ;
Kirkpatrick, Donald S. .
NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (06) :414-426
[10]   Biomarker definitions and their applications [J].
Califf, Robert M. .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2018, 243 (03) :213-221